Therapeutic Applications of Carbonic Anhydrase Inhibitors in Ophthalmology.

Simone Giovannuzzi, Alessio Nocentini, Claudiu T Supuran

Abstract readReview

In one paragraph

Review in Sub-cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Simone GiovannuzziDepartment of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Sesto Fiorentino, Florence, Italy. simone.giovannuzzi@unifi.it.

Alessio NocentiniDepartment of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Sesto Fiorentino, Florence, Italy.

Claudiu T SupuranDepartment of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Sesto Fiorentino, Florence, Italy.ORCID https://orcid.org/0000-0003-4262-0323

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ophthalmology is the branch of medicine devoted to the study, diagnosis, and treatment of disorders affecting the eye and visual system, as glaucoma is. It is a leading cause of irreversible blindness worldwide and is commonly diagnosed solely in advanced stages of the disease when important and irreversible losses of visual field have already occurred. One of the major therapeutic options for its management is based on the inhibition of the metalloenzyme Carbonic Anhydrases. Indeed, CA inhibitors (CAIs) diminish ocular hypertension in glaucomatous patients by mainly reducing the rate of bicarbonate formation and thus, the secretion of the aqueous humor. This chapter presents an overview of the current CAIs used for treating glaucoma and introduces the latest pharmaceutical advancements in this field.

Indexed as

Carbonic Anhydrase InhibitorsCarbonic AnhydrasesGlaucomaAnimalsHumansIntraocular PressureOphthalmologyCarbonic Anhydrase InhibitorsCarbonic AnhydrasesCarbonic anhydraseEnzyme inhibitionGlaucomaIOP-lowering agentsOphthalmology

Identifiers

PMID42062762

DOI10.1038/nature14650

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.